MIST Milestone Pharmaceuticals Inc

Price (delayed)

$0.862

Market cap

$107.32M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.68

Enterprise value

$79.42M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 20

. Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program ...

Highlights
Milestone Pharmaceuticals's revenue has increased by 31% QoQ
The gross profit is up by 30% since the previous quarter
MIST's quick ratio has soared by 64% YoY but it is down by 13% from the previous quarter
MIST's debt has soared by 152% YoY and by 3.3% QoQ
The net income has shrunk by 51% YoY and by 23% QoQ

Key stats

What are the main financial stats of MIST

MIST stock price

How has the Milestone Pharmaceuticals stock price performed over time
Intraday
-6.41%
1 week
-3.06%
1 month
-18.29%
1 year
-55.34%
YTD
-57.33%
QTD
-35.67%

Financial performance

How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$2.34M
Gross profit
$2.3M
Operating income
-$78.38M
Net income
-$84.01M
Gross margin
98%
Net margin
-3,585.6%
The net income has shrunk by 51% YoY and by 23% QoQ
The operating income has contracted by 42% YoY and by 20% from the previous quarter
Milestone Pharmaceuticals's revenue has increased by 31% QoQ
The gross profit is up by 30% since the previous quarter

Price vs fundamentals

How does MIST's price correlate with its fundamentals

Growth

What is Milestone Pharmaceuticals's growth rate over time

Valuation

What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.89
P/S
51.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.9
The EPS is up by 19% YoY
The P/B is 70% higher than the 5-year quarterly average of 3.7
The company's equity fell by 49% QoQ
Milestone Pharmaceuticals's revenue has increased by 31% QoQ

Efficiency

How efficient is Milestone Pharmaceuticals business performance
Milestone Pharmaceuticals's return on equity has surged by 83% YoY and by 15% QoQ
MIST's ROA is up by 30% YoY and by 6% QoQ
The ROIC has increased by 15% YoY
The ROS is up by 9% QoQ

Dividends

What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIST.

Financial health

How did Milestone Pharmaceuticals financials performed over time
The total assets is 11% greater than the total liabilities
Milestone Pharmaceuticals's total liabilities has soared by 151% YoY and by 3.6% from the previous quarter
MIST's quick ratio has soared by 64% YoY but it is down by 13% from the previous quarter
MIST's debt has soared by 152% YoY and by 3.3% QoQ
MIST's debt to equity has surged by 104% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.